Real world evidence of changes in CGRP monoclonal antibody and onabotulinumtoxinA prescription practices at the start of the COVID‐19 pandemic: An observational, retrospective study.
The article examines changes in prescription practices for CGRP monoclonal antibodies and onabotulinumtoxinA at the beginning of the COVID-19 pandemic, finding that providers initially switched to CGRP mAbs when onabotulinumtoxinA treatments were disrupted but later reverted to pre-pandemic patterns, indicating a preference for onabotulinumtoxinA when available for treating chronic migraine patients.